Healthcare


 Nanosonics Advances CORIS Platform After US Clearance

Nanosonics Advances CORIS Platform After US Clearance

March 09, 2026 07:21 PM AEDT| By Sam

Nanosonics advances its CORIS platform after US regulatory clearance expands endoscope compatibility. The development highlights progress in infection-prevention technology and strengthens the company’s position in hospital sterilisation innovation.

 Clinuvel Earnings Insight: What It Signals for ASX Healthcare

Clinuvel Earnings Insight: What It Signals for ASX Healthcare

March 09, 2026 03:59 PM AEDT| By Sam

Clinuvel Pharmaceuticals earnings update has triggered fresh valuation discussion across Australia’s biotechnology sector, highlighting product concentration dynamics and the evolving outlook for specialised healthcare innovation.

 Clinuvel Pharmaceuticals Strengthens Profile Within ASX All Ords

Clinuvel Pharmaceuticals Strengthens Profile Within ASX All Ords

March 09, 2026 01:16 PM AEDT| By Sam

Clinuvel Pharmaceuticals maintains its position within the ASX All Ords, reflecting its role in Australia’s biotechnology and healthcare sector landscape.

 ASX Market Update: Is Telix Advancing Its AI Imaging Strategy Within the ASX 200?

ASX Market Update: Is Telix Advancing Its AI Imaging Strategy Within the ASX 200?

March 06, 2026 06:36 PM AEDT| By Sam

Telix advances AI-driven prostate imaging and outlines revenue expectations, reinforcing its role in healthcare innovation within the ASX 200.

 HitIQ Seeks ASX Quotation for New Shares and Options

HitIQ Seeks ASX Quotation for New Shares and Options

March 06, 2026 04:45 PM AEDT| By Sam

An Australian sports technology company expands its capital structure through quotation of new securities, supporting development of wearable monitoring devices and advanced analytics for improved athlete safety and performance insights.

 HitIQ Director Fee Share Move Signals Governance Strategy

HitIQ Director Fee Share Move Signals Governance Strategy

March 06, 2026 04:26 PM AEDT| By Sam

A governance update highlights how an Australian technology company manages capital structure while advancing innovation in sports safety monitoring, reflecting broader trends shaping emerging businesses across the exchange.

 Recce Pharmaceuticals Ltd Weakens as All Ordinaries Healthcare Volatility Rises

Recce Pharmaceuticals Ltd Weakens as All Ordinaries Healthcare Volatility Rises

March 06, 2026 03:50 PM AEDT| By Sam

Recce Pharmaceuticals Ltd declines despite revenue expansion, reflecting widened losses and shifting sentiment within the All Ordinaries healthcare segment.

 PYC Therapeutics Update Sparks ASX Market Interest

PYC Therapeutics Update Sparks ASX Market Interest

March 06, 2026 11:25 AM AEDT| By Sam

Highlights,PYC Therapeutics expands its quoted share base on the Australian market,Additional securities may influence liquidity and trading participation,Development-focused biotechnology activity continues to attract attention,PYC Therapeutics expa...

 Rhythm Biosciences Share Update Draws Attention Across ASX Market

Rhythm Biosciences Share Update Draws Attention Across ASX Market

March 06, 2026 11:12 AM AEDT| By Sam

Rhythm Biosciences progresses quotation of additional ordinary shares, illustrating capital market engagement and the evolving role of biotechnology firms within Australia’s healthcare innovation ecosystem.

 ASX 200 Spotlight: Telix Drives Cancer AI Push

ASX 200 Spotlight: Telix Drives Cancer AI Push

March 06, 2026 01:24 AM AEDT| By Sam

Highlights,Telix expands precision oncology pipeline across major cancers,AI integration reshapes radiopharmaceutical discovery strategy,Global commercial rollout strengthens Australian biotech presence,Telix Pharmaceuticals Limited (ASX:TLX) is an A...

 Mesoblast ASX 100 Index Outlook After Earnings Update

Mesoblast ASX 100 Index Outlook After Earnings Update

March 03, 2026 05:29 PM AEDT| By Sam

Highlights,Mesoblast’s earnings update sharpens market focus on valuation outlook.,Ryoncil regulatory progress drives renewed sector attention.,Biotech sentiment shifts across the broader Australian share market.,Australia’s biotechnology landscape c...

 ASX 200 Watch: High Volume Shakes Incannex Healthcare

ASX 200 Watch: High Volume Shakes Incannex Healthcare

March 03, 2026 11:12 AM AEDT| By Sam

A surge in trading activity around a clinical-stage healthcare company highlights how liquidity, sentiment and sector dynamics interact within Australia’s evolving biotechnology landscape.

 CSL Share Price Reaction Draws Attention on ASX

CSL Share Price Reaction Draws Attention on ASX

March 02, 2026 07:15 PM AEDT| By Sam

CSL Limited share performance on the ASX gains attention as buyback activity continues and dividend timelines approach. Market sentiment also reflects broader trends across Australia’s healthcare and defensive sectors.

 Neuren Pharma Update: Buy-Back Plan And Pipeline Focus

Neuren Pharma Update: Buy-Back Plan And Pipeline Focus

March 02, 2026 06:43 PM AEDT| By Sam

Neuren Pharmaceuticals outlines earnings update, share buy-back plan and pipeline progress, highlighting royalty momentum and clinical development focus while shaping investor sentiment around the company’s neurological disorder research strategy.

 CT:VQ Approval Puts 4DMedical’s US Opportunity in Focus

CT:VQ Approval Puts 4DMedical’s US Opportunity in Focus

February 28, 2026 09:08 AM AEDT| By Sam

4DMedical’s CT:VQ approval in the U.S. highlights the company’s focus on advanced lung imaging technology, expanding healthcare adoption and strengthening its commercial strategy in the evolving global medical imaging market.

 CSL Share Price in Spotlight After Lilly Deal

CSL Share Price in Spotlight After Lilly Deal

February 27, 2026 08:23 PM AEDT| By Sam

CSL’s licensing agreement and earnings update have shifted investor focus toward valuation, margin recovery and long-term growth drivers within Australia’s healthcare sector.

 Could (ASX:CUV) Be the Next Big ASX Comeback?

Could (ASX:CUV) Be the Next Big ASX Comeback?

February 27, 2026 06:56 PM AEDT| By Sam

Clinuvel Pharmaceuticals Ltd (ASX:CUV) combines a resilient rare-disease franchise with expanding dermatology programs, positioning the biotech player at a critical stage of growth within Australia’s equity market.

 ASX 200 Spotlight: Avecho’s Governance Filing Strengthens Market Transparency

ASX 200 Spotlight: Avecho’s Governance Filing Strengthens Market Transparency

February 27, 2026 05:20 PM AEDT| By Sam

Avecho filed updated corporate governance documentation with the ASX, reinforcing structured disclosure, regulatory compliance, and transparency within the Australian healthcare sector.

 Healthcare Giants Reveal Earnings Divide

Healthcare Giants Reveal Earnings Divide

February 27, 2026 04:58 PM AEDT| By Sam

A comprehensive look at how leading Australian healthcare companies are navigating earnings recovery, integration strategy and commercial biotech expansion within the broader market landscape.

 ASX Market Signals: What 4DMedical’s Share Move Means for Traders

ASX Market Signals: What 4DMedical’s Share Move Means for Traders

February 27, 2026 04:06 PM AEDT| By Sam

This article explores how 4DMedical’s capital move highlights evolving market positioning, healthcare innovation, and broader structural changes shaping Australia’s dynamic financial ecosystem.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles






Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.